Abstract O6-methylguanine-DNA methyltransferase (MGMT) is an enzyme that removes
alkyl groups at the O6-position of guanine in DNA. MGMT expression is reduced or absent in …

Temozolomide (TMZ) is an alkylating agent currently used as first-line therapy for gliomas
treatment due to its DNA-damaging effect. However, drug resistance occurs, preventing multi …

O6-Methylguanine-DNA-methyltransferase (MGMT) is a unique protein, which both repairs
O6-alkylguanine lesions stoichiometrically without a multi-enzymatic pathway and self …

Alkylating agents such as temozolomide (TMZ) are effective anticancer drugs for treating a
variety of solid tumors including melanoma, glioma, and astrocytoma. TMZ exerts its effects …

The methylation status of the O6-methylguanine methyltransferase (MGMT) gene promoter
has been widely accepted as a prognostic biomarker for treatment with the alkylator …

Background A novel alkylating agent, temozolomide, has proven efficacious in the treatment
of malignant gliomas. However, expression of O 6-methylguanine-DNA methyltransferase …

Background: The DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT)
confers therapeutic resistance to DNA alkylating agents, including temozolomide. It is largely …

Temozolomide (TMZ) is a methylating agent which prolongs survival when administered
during and after radiotherapy in the first‐line treatment of glioblastoma and which also has …

Gliomas are the most frequent adult primary brain tumor, and are invariably fatal. The most
common diagnosis glioblastoma multiforme (GBM) afflicts 12,500 new patients in the US …

The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) is known to play
a role in sensitivity to temozolomide. Promoter hypermethylation of MGMT is commonly used …